Reneo Pharmaceuticals, Inc.
RPHM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $529 | $50 |
| Gross Profit | $0 | -$525 | -$529 | -$50 |
| % Margin | – | – | – | – |
| R&D Expenses | $43,795 | $56,088 | $37,705 | $28,169 |
| G&A Expenses | $10,591 | $25,790 | $16,143 | $11,649 |
| SG&A Expenses | $10,591 | $25,790 | $16,143 | $11,649 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $650 | $0 | $48 |
| Operating Expenses | $54,386 | $83,053 | $53,848 | $39,818 |
| Operating Income | -$54,386 | -$83,053 | -$53,848 | -$39,818 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $5,665 | $1,893 | $48 |
| Pre-Tax Income | $0 | -$77,388 | -$51,955 | -$39,770 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $0 | -$77,388 | -$50,062 | -$39,770 |
| % Margin | – | – | – | – |
| EPS | 0 | -2.3 | -2.04 | -2.19 |
| % Growth | 100% | -12.7% | 6.8% | – |
| EPS Diluted | 0 | -2.3 | -2.04 | -2.19 |
| Weighted Avg Shares Out | 34,471 | 33,614 | 24,496 | 18,143 |
| Weighted Avg Shares Out Dil | 34,471 | 33,614 | 24,496 | 18,143 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,013 | $0 | $2 | $0 |
| Interest Expense | -$300 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $170 | $529 | $50 |
| EBITDA | -$54,386 | -$82,233 | -$53,760 | -$39,768 |
| % Margin | – | – | – | – |